(Q38171402)

30 August 2017

title

Chimeric antigen receptor modified T cell therapy for B cell malignancies (English)

1 reference

30 August 2017

Cameron J Turtle

1

1 reference

30 August 2017

publication date

14 December 2013

1 reference

International Journal of Hematology

30 August 2017

published in

1 reference

30 August 2017

volume

99

1 reference

30 August 2017

issue

2

1 reference

30 August 2017

page(s)

132-140

1 reference

Adaptive immunity maintains occult cancer in an equilibrium state

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

Engineered T cells for anti-cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

T cell receptor gene therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

Genetically retargeting CD8+ lymphocyte subsets for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

A transposon and transposase system for human application

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

Facilitating matched pairing and expression of TCR chains introduced into human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

The basic principles of chimeric antigen receptor design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

Synergistic and persistent effect of T‐cell immunotherapy with anti‐CD19 or anti‐CD38 chimeric receptor in conjunction with rituximab on B‐cell non‐Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

Mathematical modeling of chimeric TCR triggering predicts the magnitude of target lysis and its impairment by TCR downmodulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

Adoptive immunotherapy with redirected T cells produces CCR7- cells that are trapped in the periphery and benefit from combined CD28-OX40 costimulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

Cytokine-independent growth and clonal expansion of a primary human CD8+ T-cell clone following retroviral transduction with the IL-15 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

Genome-wide analysis of histone methylation reveals chromatin state-based regulation of gene transcription and function of memory CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

The molecular basis of the memory T cell response: differential gene expression and its epigenetic regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

A distinct subset of self-renewing human memory CD8+ T cells survives cytotoxic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

A human memory T cell subset with stem cell-like properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

Two subsets of memory T lymphocytes with distinct homing potentials and effector functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

Inducible apoptosis as a safety switch for adoptive cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1490-X

Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24338745

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24338745

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24338745

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S12185-013-1490-X

1 reference

Dimensions Publication ID

30 August 2017

1021549038

0 references

1 reference